JP2022523961A5 - - Google Patents

Info

Publication number
JP2022523961A5
JP2022523961A5 JP2021552537A JP2021552537A JP2022523961A5 JP 2022523961 A5 JP2022523961 A5 JP 2022523961A5 JP 2021552537 A JP2021552537 A JP 2021552537A JP 2021552537 A JP2021552537 A JP 2021552537A JP 2022523961 A5 JP2022523961 A5 JP 2022523961A5
Authority
JP
Japan
Prior art keywords
domain
seq
acid sequence
nucleic acid
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021552537A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523961A (ja
Filing date
Publication date
Priority claimed from PCT/US2019/020729 external-priority patent/WO2019173324A1/en
Application filed filed Critical
Publication of JP2022523961A publication Critical patent/JP2022523961A/ja
Publication of JP2022523961A5 publication Critical patent/JP2022523961A5/ja
Priority to JP2024229572A priority Critical patent/JP2025061674A/ja
Pending legal-status Critical Current

Links

JP2021552537A 2018-03-06 2020-03-05 前立腺特異的膜抗原ｃａｒおよびその使用方法 Pending JP2022523961A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024229572A JP2025061674A (ja) 2018-03-06 2024-12-26 前立腺特異的膜抗原ｃａｒおよびその使用方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862639321P 2018-03-06 2018-03-06
USPCT/US2019/020729 2019-03-05
PCT/US2019/020729 WO2019173324A1 (en) 2018-03-06 2019-03-05 Prostate-specific membrane antigen cars and methods of use thereof
PCT/US2020/021205 WO2020181094A1 (en) 2018-03-06 2020-03-05 Prostate-specific membrane antigen cars and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024229572A Division JP2025061674A (ja) 2018-03-06 2024-12-26 前立腺特異的膜抗原ｃａｒおよびその使用方法

Publications (2)

Publication Number Publication Date
JP2022523961A JP2022523961A (ja) 2022-04-27
JP2022523961A5 true JP2022523961A5 (https=) 2023-03-08

Family

ID=67842841

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020546318A Active JP7526097B2 (ja) 2018-03-06 2019-03-05 前立腺特異的膜抗原ｃａｒおよびその使用方法
JP2021552537A Pending JP2022523961A (ja) 2018-03-06 2020-03-05 前立腺特異的膜抗原ｃａｒおよびその使用方法
JP2024020832A Pending JP2024056890A (ja) 2018-03-06 2024-02-15 前立腺特異的膜抗原ｃａｒおよびその使用方法
JP2024229572A Pending JP2025061674A (ja) 2018-03-06 2024-12-26 前立腺特異的膜抗原ｃａｒおよびその使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020546318A Active JP7526097B2 (ja) 2018-03-06 2019-03-05 前立腺特異的膜抗原ｃａｒおよびその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024020832A Pending JP2024056890A (ja) 2018-03-06 2024-02-15 前立腺特異的膜抗原ｃａｒおよびその使用方法
JP2024229572A Pending JP2025061674A (ja) 2018-03-06 2024-12-26 前立腺特異的膜抗原ｃａｒおよびその使用方法

Country Status (10)

Country Link
US (3) US10780120B2 (https=)
EP (2) EP3762410A4 (https=)
JP (4) JP7526097B2 (https=)
KR (1) KR20200130709A (https=)
CN (1) CN112119157B (https=)
AU (2) AU2019231205A1 (https=)
CA (2) CA3093078A1 (https=)
MX (1) MX2020009272A (https=)
TW (2) TW201940520A (https=)
WO (2) WO2019173324A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010099205A1 (en) * 2009-02-24 2010-09-02 The Trustees Of The University Of Pennsylvania Methods for treating progressive multifocal leukoencephalopathy (pml)
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
KR102211837B1 (ko) 2013-01-14 2021-02-03 젠코어 인코포레이티드 신규한 이형이량체 단백질
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
PE20171324A1 (es) 2014-11-26 2017-09-11 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
EP3223907A2 (en) 2014-11-26 2017-10-04 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
CN109715663B (zh) 2016-06-28 2022-11-25 Xencor股份有限公司 结合生长抑素受体2的异源二聚抗体
GB201614162D0 (en) * 2016-08-18 2016-10-05 Polytherics Ltd Antibodies, uses thereof and conjugates thereof
WO2018191490A1 (en) * 2017-04-13 2018-10-18 The Trustees Of The University Of Pennsylvania Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy
JP2021502100A (ja) 2017-11-08 2021-01-28 ゼンコア インコーポレイテッド 新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体
MX2020009272A (es) * 2018-03-06 2021-01-08 Univ Pennsylvania Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos.
CA3096052A1 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
EP3829312A4 (en) * 2018-08-04 2022-07-06 Abcyte Therapeutics Inc. MULTIFUNCTIONAL AND MULTI-TARGETING CAR SYSTEM AND METHODS OF USE
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
GB201919019D0 (en) * 2019-12-20 2020-02-05 Autolus Ltd Antigen-binding domain
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
AU2021286655A1 (en) * 2020-06-12 2023-01-05 Nkarta, Inc. Genetically modified natural killer cells for CD70-directed cancer immunotherapy
IL297697A (en) * 2020-06-17 2022-12-01 Tiziana Life Sciences Plc Preparations and methods for improving chimeric antigen receptor t cell therapies
CA3198363A1 (en) * 2020-10-09 2022-04-14 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods and compositions comprising pd1 chimeric polypeptides
WO2022087435A1 (en) * 2020-10-23 2022-04-28 Hq Han Bifunctional antagonists of tumor necrosis factor-alpha and transforming growth factor-beta and uses thereof
US20220144956A1 (en) * 2020-11-06 2022-05-12 Xencor, Inc. HETERODIMERIC ANTIBODIES THAT BIND TGFbetaRII
KR20230124656A (ko) * 2020-12-24 2023-08-25 카이트 파마 인코포레이티드 전립선암 키메라 항원 수용체
AR124826A1 (es) * 2021-02-08 2023-05-10 Hutchinson Fred Cancer Res Sistema y métodos para vincular la señalización de cd40 a la unión del antígeno
US11739144B2 (en) 2021-03-09 2023-08-29 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CLDN6
EP4305065A1 (en) 2021-03-10 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
CA3219447A1 (en) * 2021-05-26 2022-12-01 Baisong Lu Gene therapy for dent disease
CN113621077B (zh) * 2021-09-02 2023-01-31 山东大学 一种tim-3/cd28融合蛋白及所述融合蛋白修饰的car-t细胞
CN117229385A (zh) * 2022-06-06 2023-12-15 北京卡替医疗技术有限公司 Pd-1变体及其用途
CN116284409A (zh) * 2022-07-08 2023-06-23 上海优替济生生物医药有限公司 Gpc3 car-t细胞及其在制备治疗癌症的药物中的用途
AU2023321765A1 (en) * 2022-08-11 2025-03-20 Adicet Therapeutics, Inc. Affinity binding entities directed to psma and methods of use thereof
CN116178567B (zh) * 2022-10-28 2025-01-28 四川大学华西医院 一种靶向TGFβRII的嵌合抗原受体及其用途
WO2024103107A1 (en) * 2022-11-14 2024-05-23 Peter Maccallum Cancer Institute Fusion proteins and uses thereof
IL322949A (en) 2023-03-03 2025-10-01 Arsenal Biosciences Inc Systems targeting PSMA and CA9
WO2025096433A1 (en) * 2023-10-30 2025-05-08 Eureka Therapeutics, Inc. Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
CN118027203A (zh) * 2023-12-11 2024-05-14 合肥天港免疫药物有限公司 Psma抗体及其应用

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992010591A1 (en) 1990-12-14 1992-06-25 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
US5912170A (en) 1991-03-07 1999-06-15 The General Hospital Corporation Redirection of cellular immunity by protein-tyrosine kinase chimeras
IE920716A1 (en) 1991-03-07 1992-09-09 Gen Hospital Corp Redirection of cellular immunity by receptor chimeras
AU671606B2 (en) 1991-10-31 1996-09-05 Whitehead Institute For Biomedical Research TGF-beta type receptor cDNAs and uses therefor
WO1993019163A1 (en) 1992-03-18 1993-09-30 Yeda Research And Development Co, Ltd. Chimeric receptor genes and cells transformed therewith
DE69332026T2 (de) 1992-10-29 2002-10-31 Celtrix Pharmaceuticals, Inc. Typ ii tgf-beta-bindendes rezeptorfragment als therapeutisches mittel
DE69334071T2 (de) 1992-11-05 2007-10-25 Sloan-Kettering Institute For Cancer Research Prostata-spezifisches membranantigen
KR100278352B1 (ko) 1993-07-16 2001-01-15 어니스트 엠. 해데드 수용체 키메라에 의한 세포 면역성의 전환
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
ATE297986T1 (de) 1995-02-24 2005-07-15 Gen Hospital Corp Neuorientierung der zellulären immunität durch rezeptorchimären
EP0914155B1 (en) 1996-03-25 2006-02-22 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
NZ500284A (en) 1997-04-18 2001-09-28 Biogen Inc Type II TGF-beta receptor fusion proteins
MY131805A (en) 1997-09-18 2007-09-28 Biogen Idec Inc Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis.
AU4572899A (en) 1998-06-16 2000-01-05 Biogen, Inc. Variant type ii tgf-beta receptor fusion proteins and methods
EP1109921A4 (en) 1998-09-04 2002-08-28 Sloan Kettering Inst Cancer FUSION RECEPTORS SPECIFIC TO MEMBRANE SPECIFIC PROSTATIC ANTIGEN AND USES THEREOF
AU771635B2 (en) 1999-01-05 2004-04-01 American National Red Cross, The Methods for treating conditions associated with the accumulation of excess extracellular matrix
NZ517331A (en) 1999-07-29 2004-02-27 Medarex Inc Human monoclonal antibodies to prostate specific membrane antigen and a transgenic mouse to produce the antibody
WO2002098897A2 (en) 2001-06-01 2002-12-12 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
JP5355839B2 (ja) 2001-10-23 2013-11-27 ピーエスエムエー デベロプメント カンパニー， エル．エル．シー． Ｐｓｍａ抗体およびタンパク質マルチマー
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
EP2336189A1 (en) 2003-01-28 2011-06-22 Proscan RX Pharma Prostate cancer diagnosis and treatment
US20050113564A1 (en) 2003-11-05 2005-05-26 St. Jude Children's Research Hospital Chimeric receptors with 4-1BB stimulatory signaling domain
JP2008529556A (ja) * 2005-02-18 2008-08-07 メダレックス， インク． 前立腺特異的膜抗原（ｐｓｍａ）に対するヒトモノクローナル抗体
CN101160324B (zh) 2005-02-18 2013-04-24 米德列斯公司 缺乏岩藻糖残基的抗前列腺特异性膜抗原(psma)单克隆抗体
DK2352763T4 (da) * 2008-10-01 2022-10-17 Amgen Res Munich Gmbh Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener
AU2010325969B2 (en) 2009-12-02 2016-10-20 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen
CA3253628A1 (en) * 2010-03-05 2025-11-29 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
ES2602743T3 (es) 2010-09-08 2017-02-22 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Receptores de antígenos quiméricos con una región bisagra optimizada
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
KR20140004174A (ko) 2011-01-18 2014-01-10 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암 치료를 위한 조성물 및 방법
CA2832569A1 (en) 2011-04-08 2012-10-11 Baylor College Of Medicine Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
MX2014001222A (es) * 2011-07-29 2014-09-15 Univ Pennsylvania Receptores coestimuladores de cambio.
CN103946952A (zh) * 2011-09-16 2014-07-23 宾夕法尼亚大学董事会 用于治疗癌症的rna改造的t细胞
ES2654060T3 (es) * 2011-10-20 2018-02-12 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Receptores de antígenos quiméricos anti-CD22
WO2013126726A1 (en) * 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
US20140099257A1 (en) 2012-10-05 2014-04-10 Cornell University Androgen Suppression, Prostate-Specific Membrane Antigen and the Concept of Conditionally Enhanced Vulnerability
US10584158B2 (en) 2013-04-17 2020-03-10 Baylor College Of Medicine Immunosuppressive TGF-β signal converter
US20170335281A1 (en) 2014-03-15 2017-11-23 Novartis Ag Treatment of cancer using chimeric antigen receptor
EP4166148B1 (en) 2014-06-06 2026-02-18 Memorial Sloan-Kettering Cancer Center Mesothelin-targeted chimeric antigen receptors and uses thereof
SI3151672T1 (sl) 2014-06-06 2021-03-31 Bluebird Bio, Inc. Izboljšani T-celični sestavki
SG10201913782UA (en) * 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cll-1 chimeric antigen receptor
EP4205749A1 (en) 2014-07-31 2023-07-05 Novartis AG Subset-optimized chimeric antigen receptor-containing cells
EP3193933B1 (en) * 2014-09-17 2021-04-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Anti-cd276 antibodies (b7h3)
BR112017007003A2 (pt) 2014-10-07 2017-12-19 Cellectis método para modulação de atividade de células imunes induzidas por car
MA41046A (fr) 2014-10-10 2017-08-15 Memorial Sloan Kettering Cancer Center Thérapies liées au psma
MA41538A (fr) 2014-10-17 2017-12-26 Baylor College Medicine Cellules immunitaires bipartites et tripartites de signalisation
US20170335331A1 (en) 2014-10-31 2017-11-23 The Trustees Of The University Of Pennsylvania Altering Gene Expression in CART Cells and Uses Thereof
US10828353B2 (en) * 2015-01-31 2020-11-10 The Trustees Of The University Of Pennsylvania Compositions and methods for T cell delivery of therapeutic molecules
MA41920B1 (fr) * 2015-04-06 2021-05-31 Acceleron Pharma Inc Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations
DE102015211108A1 (de) * 2015-06-17 2016-12-22 Robert Bosch Gmbh Vorrichtung und Verfahren zur Ausführung eines Rechenverfahrens
DK3909972T5 (da) 2015-06-19 2024-08-05 Sebastian Kobold Pd1-cd28-fusionsproteiner og disses anvendelse i medicin
US11655452B2 (en) 2015-06-25 2023-05-23 Icell Gene Therapeutics Inc. Chimeric antigen receptors (CARs), compositions and methods of use thereof
WO2017032293A1 (zh) * 2015-08-21 2017-03-02 科济生物医药（上海）有限公司 抗间皮素全人抗体以及靶向间皮素的免疫效应细胞
CN108348551A (zh) 2015-08-28 2018-07-31 宾夕法尼亚大学董事会 表达嵌合细胞内信号传导分子的细胞的方法和组合物
CA2997551A1 (en) * 2015-09-04 2017-03-09 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use
US20170232070A1 (en) 2015-10-23 2017-08-17 Richard P. Junghans Combination Methods for Immunotherapy
JP7123794B2 (ja) 2015-12-09 2022-08-23 メモリアル スローン ケタリング キャンサー センター 免疫細胞組成物及びそれを使用する方法
EP3464379B1 (en) 2016-06-06 2023-09-27 Abzena (UK) Limited Antibodies, uses thereof and conjugates thereof
GB201614162D0 (en) 2016-08-18 2016-10-05 Polytherics Ltd Antibodies, uses thereof and conjugates thereof
CN109863242A (zh) 2016-08-30 2019-06-07 纪念斯隆-凯特林癌症中心 用于治疗病毒感染和其它感染的免疫细胞组合物和使用方法
ES2912408T3 (es) 2017-01-26 2022-05-25 Novartis Ag Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos
WO2018191490A1 (en) 2017-04-13 2018-10-18 The Trustees Of The University Of Pennsylvania Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy
MX2020009272A (es) * 2018-03-06 2021-01-08 Univ Pennsylvania Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos.

Similar Documents

Publication Publication Date Title
JP2022523961A5 (https=)
CN112074279B (zh) 人源化bcma抗体和bcma-car-t细胞
US11180553B2 (en) Chimeric antigen receptor
EP3240805B1 (en) Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
CN109069537B (zh) 共刺激结构域中具有重复结合基序的car
CN103483452B (zh) 双信号独立的嵌合抗原受体及其用途
JP2019150066A5 (https=)
CN109053899B (zh) 一种含人转铁蛋白抗原表位序列的嵌合体抗原受体
CN114391021B (zh) TGF-β受体和使用方法
WO2016113203A1 (en) Engineered t cells and uses therefor
BR112020007319A2 (pt) célula
CN112154204A (zh) 基因工程化的细胞及应用
JP2019535262A5 (https=)
JP2018536434A (ja) 腫瘍形質導入のための組成物及び方法
WO2018045034A1 (en) Chimeric antigen receptors having gitr intracellular domain as co-stimulatory domain
JP2024504728A5 (https=)
JP2025069175A (ja) 挿着されている細胞に直接シグナル伝達しない非天然ｎｋｇ２ｄ受容体
JP2022529380A5 (https=)
CN112996819A (zh) 细胞分选系统及使用方法
WO2023147515A1 (en) Methods of manufacturing cellular compositions
JP2024534783A5 (https=)
JP2023516089A (ja) がんの治療のための組成物及び方法
CN114007626A (zh) 用于治疗癌症的组合物和方法
CN114685659B (zh) Cd22特异性人源化抗体及利用其的嵌合抗原受体
WO2023137364A2 (en) Sars-cov-2 therapies